Ophthalmology

Top Story

BLOG: Roclatan — Works like a combo, acts like a prostaglandin

BLOG: Roclatan — Works like a combo, acts like a prostaglandin
September 27, 2016

The initial therapy for standard of care in glaucoma has been topical drops for a very long time. Although we are constantly working on better ways to deliver medications and perform surgery, primary and adjunctive therapies still depend on eye drops. The major obstacle remains the same: patient compliance and the factors that influence it. It is great having more drop options, especially after prostaglandin analogues. Unfortunately, we all know our patients’ ability to effectively get these in their eyes remains the major limiting step. This occurs for many factors. Dosing regimens for topical medications can be complicated, which is further exacerbated if the patient has other systemic diseases requiring oral drugs. Other factors include the side effects beyond those to the eyes that can be quite serious, including systemic, and the inability to effectively apply eye drops.

Patients simply do better when these compounding issues that affect compliance are minimized. However, more than 50% of patients need more than one class of therapy. Every time a patient misses a dose, no matter the reason, there is additional damage to the optic nerve. The cumulative effect can be devastating. Currently, the selection of therapy from adjunctive options is simply a compromise among efficacy, safety and dosing instead of an ideal choice. The ideal situation would include maintaining the patient on just one drop a day like a prostaglandin but getting more IOP reduction. Until recently this has not been possible because current medications have not been combined with prostaglandins in the United States.

Video

Speaker relates approach to dry eye therapy

September 27, 2016
According to Sumit Garg, MD, dry eye disease affects 29 million people in the U.S. and is the most common presenting symptom in the general ophthalmologist's practice…
In the Journals

Exfoliation syndrome may be more common in women with pelvic organ prolapse

September 26, 2016
Women with pelvic organ prolapse were more likely to be diagnosed with exfoliation syndrome, according to a study using the Utah Population Database. Researchers split…
In the Journals

Physicians debate ACGME's Milestones initiative

September 26, 2016
The Accreditation Council for Graduate Medical Education’s Milestones initiative and its role in internal medicine are a source of debate for physicians. …
Video

Speaker reviews use of laser in retinal disease

September 26, 2016
At Retina 2016, Elias Reichel, MD, focuses on the use of panretinal photocoagulation to treat branch retinal vein occlusion, center-involving diabetic macular edema and…
More News Headlines »
Original Article

Retinoblastoma Control With Primary Intra-arterial Chemotherapy: Outcomes Before and During the Intravitreal Chemotherapy Era

Journal of Pediatric Ophthalmology and Strabismus, September/October 2016, Volume 53 Issue 5
To compare outcomes of intra-arterial chemotherapy for retinoblastoma as primary therapy before (Era I) and during (Era…
More »
CME

Comparative Treatment Trials for Wet AMD: A Comprehensive Review

This activity is supported by educational grants from Allergan, Inc.; Genentech, Inc.; and Regeneron Pharmaceuticals, Inc.

The advent of intravitreal therapies to treat retinal diseases has revolutionized the management of retinal pathology…
More »
Featured
Video
Meeting News Coverage

VIDEO: Surgeon focuses on breakthrough cataract surgery technologies

September 19, 2016
More »
morganatic-roan